Furthermore, topo I-APC+ topo I-PE+ CD19+ cells from the topo I-induced SSc model mice treated with the BTK inhibitor exhibited significantly lower affinity for topo I relative to the model mice without the BTK inhibitor (p<0.005; Figure 7B). Here, BTK is linked to systemic sclerosis.